MX2016002273A - Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib. - Google Patents

Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.

Info

Publication number
MX2016002273A
MX2016002273A MX2016002273A MX2016002273A MX2016002273A MX 2016002273 A MX2016002273 A MX 2016002273A MX 2016002273 A MX2016002273 A MX 2016002273A MX 2016002273 A MX2016002273 A MX 2016002273A MX 2016002273 A MX2016002273 A MX 2016002273A
Authority
MX
Mexico
Prior art keywords
antagonist
dinaciclib
combination
treating cancer
combination therapies
Prior art date
Application number
MX2016002273A
Other languages
English (en)
Inventor
Joseph H Phillips
Peter Richard Strack
Robert Booher
Venkataraman Sriram
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016002273A publication Critical patent/MX2016002273A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente revelación describe las terapias de combinación que comprenden un antagonista del receptor de Muerte Programada 1 (PD-1) y el inhibidor de CDK dincaciclib, y el uso de las terapias de combinación para el tratamiento del cáncer, y en particular para el tratamiento de cánceres que expresan la PD-L1.
MX2016002273A 2013-08-20 2014-08-15 Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib. MX2016002273A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361867760P 2013-08-20 2013-08-20
PCT/US2014/051171 WO2015026634A1 (en) 2013-08-20 2014-08-15 Treating cancer with a combination of a pd-1 antagonist and dinaciclib

Publications (1)

Publication Number Publication Date
MX2016002273A true MX2016002273A (es) 2016-05-31

Family

ID=52484060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002273A MX2016002273A (es) 2013-08-20 2014-08-15 Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.

Country Status (11)

Country Link
US (1) US9827309B2 (es)
EP (1) EP3035964B1 (es)
JP (1) JP6586087B2 (es)
KR (1) KR102232153B1 (es)
CN (1) CN105451770B (es)
AU (1) AU2014309199B2 (es)
CA (1) CA2920113A1 (es)
ES (1) ES2827679T3 (es)
MX (1) MX2016002273A (es)
RU (1) RU2705795C2 (es)
WO (1) WO2015026634A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3222634A1 (en) * 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
MX2015007051A (es) 2012-12-07 2016-01-12 Chemocentryx Inc Diazol lactamas.
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
AU2015345199A1 (en) * 2014-11-10 2017-04-27 Ventana Medical Systems, Inc. Classifying nuclei in histology images
EP3256161A1 (en) 2015-02-09 2017-12-20 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
WO2016144673A1 (en) * 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
US11243205B2 (en) 2015-05-22 2022-02-08 Peter Maccallum Cancer Institute Method of diagnosis of breast cancer
US10869924B2 (en) * 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
TN2017000554A1 (en) * 2015-07-29 2019-04-12 Novartis Ag Novel combination for use in the treatment of cancer
RU2731202C2 (ru) * 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
KR102491013B1 (ko) 2016-03-24 2023-01-31 코테라 바이오사이언스 인코포레이티드 Tg02를 사용한 암의 치료
WO2017176965A1 (en) 2016-04-07 2017-10-12 Chemocentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
AU2017249078B2 (en) 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
MA45025A (fr) 2016-05-20 2019-03-27 Lilly Co Eli Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1
CN109152838A (zh) * 2016-05-23 2019-01-04 伊莱利利公司 用于治疗癌症的派姆单抗和玻玛西尼的组合
WO2017205213A1 (en) * 2016-05-23 2017-11-30 Eli Lilly And Company Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer
WO2017205514A1 (en) * 2016-05-25 2017-11-30 Case Western Reserve University Methods of sensitizing cancer to immunotherapy
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
EP3512519A1 (en) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Syk inhibitors
WO2018057303A1 (en) * 2016-09-26 2018-03-29 Imclone Llc Combination therapy for cancer
CA3035681A1 (en) 2016-09-29 2018-04-05 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
MX2019004621A (es) 2016-11-02 2019-11-28 Engmab Sarl Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
EP3533804A4 (en) * 2016-11-18 2020-06-17 Beijing Hanmi Pharmaceutical Co., Ltd. BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF
US20200009134A1 (en) * 2017-03-03 2020-01-09 Gritscience Biopharmaceuticals Co., Ltd. Method and Compound for Modifying Circadian Clock
EP3600426A4 (en) * 2017-03-31 2021-01-20 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND AN ANTI-CTLA4 ANTIBODY
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2019005635A2 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. ANTI-PD-1 ANTIBODIES AND METHODS OF PREPARATION AND USE
CN111712242B (zh) 2017-09-25 2023-11-24 凯莫森特里克斯股份有限公司 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗
JP7378394B2 (ja) 2017-11-03 2023-11-13 オーリジーン オンコロジー リミテッド Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
WO2019136368A2 (en) 2018-01-08 2019-07-11 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN110215516A (zh) * 2018-03-02 2019-09-10 南京大学 一种抑制cdk5协同免疫治疗在抑制乳腺癌中的应用
AU2019281358A1 (en) 2018-06-03 2021-01-07 Lamkap Bio Beta Ltd. Bispecific antibodies against CEACAM5 and CD47
US11090286B2 (en) * 2018-06-15 2021-08-17 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
EP3820496A4 (en) * 2018-07-09 2022-04-20 Precigen, Inc. FUSION CONSTRUCTS AND METHODS OF USE THEREOF
CN110613850A (zh) * 2019-05-24 2019-12-27 中国医学科学院北京协和医院 周期蛋白依赖性激酶1抑制剂及其用途
US20230136228A1 (en) 2019-09-18 2023-05-04 Lamkap Bio Alpha AG Bispecific antibodies against ceacam5 and cd3
US20210128725A1 (en) * 2019-11-04 2021-05-06 Northwestern University Cytotoxic lipid particles targeted to tumor-associated myeloid cells (tamcs) and synergized with radiation therapy for treating glioblastoma
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP4076385A1 (en) * 2019-12-20 2022-10-26 Formycon AG Formulations of anti-pd1 antibodies
JPWO2022004760A1 (es) 2020-06-30 2022-01-06
AU2021345096A1 (en) * 2020-09-17 2023-04-20 Merck Sharp & Dohme Llc Dosing regimens of anti-ILT4 antibody or its combination with anti-PD-1 antibody for treating cancer
IL301701A (en) 2020-12-18 2023-05-01 Lamkap Bio Beta Ag Bispecific antibodies against CEACAM5 and CD47
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE69942671D1 (de) 1998-12-01 2010-09-23 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US20100055111A1 (en) 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
NZ584037A (en) 2007-09-17 2012-08-31 Schering Corp Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
US20100286038A1 (en) * 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
TR201810298T4 (tr) 2011-03-31 2018-08-27 Merck Sharp & Dohme İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler.
MY193562A (en) * 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
CA2895284A1 (en) * 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Also Published As

Publication number Publication date
ES2827679T3 (es) 2021-05-24
US9827309B2 (en) 2017-11-28
CA2920113A1 (en) 2015-02-26
JP6586087B2 (ja) 2019-10-02
WO2015026634A1 (en) 2015-02-26
RU2016109811A (ru) 2017-09-22
RU2705795C2 (ru) 2019-11-12
RU2016109811A3 (es) 2018-06-19
KR102232153B1 (ko) 2021-03-24
EP3035964A1 (en) 2016-06-29
JP2016528286A (ja) 2016-09-15
CN105451770B (zh) 2020-02-07
CN105451770A (zh) 2016-03-30
AU2014309199A1 (en) 2016-02-18
AU2014309199B2 (en) 2018-04-19
KR20160044480A (ko) 2016-04-25
EP3035964B1 (en) 2020-09-23
US20160193334A1 (en) 2016-07-07
EP3035964A4 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
MX2016002273A (es) Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
SG10201806656UA (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
PH12016501550A1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
TW201613635A (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
PH12017501857A1 (en) Pd-l1 antagonist combination treatments
ZA201806633B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
MX2017015308A (es) Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer.
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
MA40344A (fr) Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
MY195110A (en) Antibodies to PD-1 and uses Thereof
PH12015502091A1 (en) Cdc7 inhibitors
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MA40364A (fr) Polythérapie pour le traitement du cancer
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.

Legal Events

Date Code Title Description
FG Grant or registration